R Iannini

Temporary henna tattoo is unsafe in atopic children.

Temporary henna tattoos have become increasingly popular as a safe alternative to permanent tattoos among American and European children and teenagers during the summer holidays. Currently, temporary henna tattoos contain not only henna, but also other additives such as para‐phemylenediamine (PPD), which is considered to be the chemical agent that most frequently causes skin reactions associated with the use of commercial black henna.

Happy Air®, a Successful School-Based Asthma Educational and Interventional Program for Primary School Children

Background. To investigate whether an active partnership between schools, parents, and pediatricians can improve the management of asthma and quality of life of children with asthma. Methods. A comprehensive asthma program (Happy Air®), based on a strong family–physician–school relationship, was carried out over a period of 3 years in six primary schools (2765 children). This program provides educational intervention to families, school staff, and students, as well as the administration of written questionnaires to identify children with asthma, asthma diagnosis and management, and, last but not least, extracurricular activities to improve respiratory and psychological conditions. Quality of life of children and parents, at the beginning and end of the program, was assessed using PedsQL™ 4.0 (Pediatric Quality of Life Inventory) measurement model. Result. Asthma was diagnosed in 135 children, of which 37 (27%) were diagnosed de novo. In all children, both single item and total clinical asthma scores showed a significant increase (p < .001) at the end of the Happy Air® program. The average scores of both the total PedsQL™ 4.0 and the four Scales were significantly increased (p < .001). Conclusion. Happy Air® is a model for a strategy of education- and school-based intervention for children with asthma and their families. This multi-action program for diagnosis, clinical follow-up, education, self-management, and quality-of-life control aims to minimize the socioeconomic burden of asthma disease.

Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not?

The identification of a Btk mutation in a male patient with <2% CD19(+) B cells warrants making the diagnosis of X-linked Agammaglobulinemia (XLA). Herein we report the case of a 31 year-old male with a gradual decline of peripheral B lymphocytes and low IgA and IgM but normal IgG levels. His clinical history revealed recurrent respiratory and skin infections, sclerosing cholangitis and chronic obstructive pancreatitis. Molecular studies revealed a novel aminoacidic substitution in Btk protein (T316A). His mother, maternal aunts and a maternal female cousin were heterozygotes for the same Btk mutation and were variably affected with pulmonary emphysema. This is a puzzling case where the patients clinical history and laboratory findings divorce molecular genetics. Either this case confirms the variable expressivity of XLA disease or the T316A change in Btk SH2 domain is a novel non-pathogenic mutation and another unknown gene alteration is responsible for the disease.

Happy Air®: A School-Based Educational Program to Maximize Detection of Asthma in Children

Objective. To investigate whether an active partnership among school, parents, and pediatricians allows early identification and treatment of asthmatic children. Methods: An asthma educational program (Happy Air®), based on a strong family-physician-school interrelationship, was performed in six primary schools (2,765 children) before administering a screening questionnaire to the parents. Results. A high response rate (96%) demonstrated 2,649 responders available for the asthma screening: 135 children (5%) received a diagnosis of asthma, of which 37 (27%) were recognized de novo. Conclusion. The active participation of school and parents is the determining factor for the success of an asthma screening program.

GSTP1*B allele increases the risk for asthma in children.

Paolo Gravina*, Federica Angelini, Marco Chianca, Alessandra Valentini, Lorenza Bellincampi, Roberta Iannini, Andrea Pierantozzi, Viviana Moschese, Elisabetta Mrak, Giorgio Federici, Loredana Chini and Sergio Bernardini 1 Department of Laboratory Medicine, Clinical Molecular Biology Laboratory, PTV, Rome, Italy 2 Department of Internal Medicine, Tor Vergata University, Rome, Italy 3 Department of Paediatrics, Tor Vergata University, Rome, Italy 4 Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy